Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in bone marrow transplantation.

M R Vowels1

  • 1Prince of Wales Children's Hospital, Randwick, New South Wales, Australia.

Australian Paediatric Journal
|December 1, 1987
PubMed
Summary

Bone marrow transplantation (BMT) strategies effectively manage graft-versus-host disease (GVHD) and infections. Survival rates vary by leukemia type and disease stage, with significant cures for beta-thalassemia major and aplastic anemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group.

Bone marrow transplantation·2008
Same author

Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation.

Bone marrow transplantation·2007
Same author

Allogeneic bone marrow transplant improves outcome for juvenile myelomonocytic leukaemia.

Journal of paediatrics and child health·2002
Same author

Prolonged ex vivo culture of cord blood CD34(+) cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model.

British journal of haematology·2001
Same author

Prior cryopreservation of ex vivo-expanded cord blood cells is not detrimental to engraftment as measured in the NOD-SCID mouse model.

Journal of hematotherapy & stem cell research·2001
Same author

Conditions that enable human hematopoietic stem cell engraftment in all NOD-SCID mice.

Transplantation·2001

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Bone marrow transplantation (BMT) faces challenges including graft-versus-host disease (GVHD), infections, rejection, and relapse.
  • GVHD is a major barrier, with combined methotrexate and cyclosporine showing superior control compared to monotherapy.
  • Cytomegalovirus (CMV) interstitial pneumonitis is a significant cause of mortality post-BMT.

Purpose of the Study:

  • To review current strategies for overcoming major barriers in bone marrow transplantation.
  • To evaluate the efficacy of different immunosuppressive regimens and T-cell depletion in managing GVHD.
  • To assess survival outcomes for various hematologic malignancies and genetic disorders treated with BMT.

Main Methods:

  • Review of immunosuppressive therapies, including methotrexate and cyclosporine, for GVHD prophylaxis and treatment.
  • Analysis of T-cell depletion techniques in donor marrow to mitigate GVHD.
  • Evaluation of prophylactic measures against cytomegalovirus (CMV) infection, such as CMV hyperimmune globulin and donor screening.
  • Assessment of radiation fractionation protocols to reduce toxicity.
  • Compilation of survival data for BMT in acute non-lymphoblastic leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, beta-thalassemia major, and severe aplastic anemia.

Main Results:

  • Combination therapy with methotrexate and cyclosporine is more effective for GVHD control than either agent alone.
  • T-cell depletion reduces GVHD but may increase relapse risk and rejection rates (5-10%).
  • CMV hyperimmune globulin and use of CMV-negative blood donors can prevent CMV interstitial pneumonitis.
  • Fractionated total body irradiation offers decreased toxicity compared to single-dose irradiation.
  • Four-year disease-free survival rates: 75% for AML in first remission, 50% for ALL in second remission, 88% for CML in chronic phase.
  • BMT cures 80% of young beta-thalassemia major patients without organ dysfunction and shows similar success in severe aplastic anemia if performed before transfusions.

Conclusions:

  • Current BMT protocols demonstrate significant progress in managing GVHD, infections, and improving survival rates for various hematologic conditions.
  • Tailored approaches, including specific immunosuppression, T-cell manipulation, and infection prophylaxis, are crucial for successful BMT outcomes.
  • BMT offers curative potential for beta-thalassemia major and severe aplastic anemia, emphasizing the importance of early intervention.

Related Experiment Videos